We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
RenovoRx announced the U.S. Food and Drug Administration (FDA) has granted the Company orphan drug designation for treating bile duct cancer, also known as cholangiocarcinoma, with intra-arterial gemcitabine.